- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03527563
Study on Internet Medical Models for the Management of Patients With Hypertension in China
A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Protocol Title:A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients with Hypertension in China Study Indication:Hypertension Number of Site:16sites Study Duration (from the initiation of the first site to the end of the follow-up for the last subject): 12 months Duration of Treatment and Management: 6 months Planned Number of Subjects:958 subjects, 479 in each group(blood pressure management in Internet medical model, Conventional medical model) Internet Medical Model:Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
Conventional Medical Model:Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
Inclusion Criteria:
- Male or female, 45 to 75 years old (including 45and 75 years);
- Two measurements of resting systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg on different days during screening;
Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:
- Oral contraceptive, either combined or progestogen alone.
- Injectable progestogen.
- Implants of levonorgestrel.
- Oestrogenic vaginal ring.
- Percutaneous contraceptive patches.
- Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
- Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
- Subjects who can understand and perform home blood pressure monitoring as required by the study;
- Subjects who voluntarily participate in the study and sign informed consent form.
Exclusion Criteria:
- Two measurements of resting systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg on different days during screening;
- Subjects with the history of cerebral stroke within 6 months prior to screening;
- Subjects with the history of myocardial infarction within 6 months prior to screening;
- Subjects with the history of heart failure;
- Subjects with the history of atrial fibrillation;
- Subjects with the history of coronary artery revascularization;
- Subjects with other serious diseases, such as tumor;
- Subjects diagnosed as the secondary hypertension;
- Subjects with congenital or acquired organic heart disease;
- Pregnant or lactant subjects;
- Subjects with severe mental disease;
- Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine > 2X upper limit value
- Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
- Subjects who are unable to conduct blood pressure self-test;
- The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.
Efficacy Evaluations:
Primary Efficacy Endpoints:
- Blood pressure control rate of subjects in the two groups at Month 6 Secondary Efficacy Endpoints:
- Blood pressure control rate of subjects in the two groups at Month 3
- Blood pressure value of subjects in the two groups at Month 3 and Month 6
- Change of blood pressure of subjects in the two groups at Month 3 and Month 6
- Variability of blood pressure of subjects in the two groups at Month 3 and Month 6
- Treatment compliance of subjects in the two groups at Month 3 and Month 6
- Medical expense of subjects in the two groups at Month 3 and Month 6
- Treatment satisfaction of subjects in the two groups at Month 3 and Month 6
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: jie jiang, doctor
- Numero di telefono: 13601155975
- Email: jiangjie417@vip.163.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female, 45 to 75 years old (including 45 and 75 years);
- Two measurements of resting systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg on different days during screening;
Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:
Oral contraceptive, either combined or progestogen alone. Injectable progestogen. Implants of levonorgestrel. Oestrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
- Subjects who can understand and perform home blood pressure monitoring as required by the study;
- Subjects who voluntarily participate in the study and sign informed consent form.
Exclusion Criteria:
- Two measurements of resting systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg on different days during screening;
- Subjects with the history of cerebral stroke within 6 months prior to screening;
- Subjects with the history of myocardial infarction within 6 months prior to screening;
- Subjects with the history of heart failure;
- Subjects with the history of atrial fibrillation;
- Subjects with the history of coronary artery revascularization;
- Subjects with other serious diseases, such as tumor;
- Subjects diagnosed as the secondary hypertension;
- Subjects with congenital or acquired organic heart disease;
- Pregnant or lactant subjects;
- Subjects with severe mental disease;
- Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine >2 X upper limit value;
- Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
- Subjects who are unable to conduct blood pressure self-test;
- The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: Internet Medical Model
Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
|
Subjects in the Internet group should upload blood pressure monitoring data at least once per day.
It is highly recommended to upload two pressure monitoring results to capture more blood pressure information.
The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg.
After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician.
Then the frequency of communication will be changed to once a month.
Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
|
Nessun intervento: Conventional Medical Model
Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Primary endpoint: blood pressure control rate of subjects in the two groups at Month 6
Lasso di tempo: 6 months
|
Definition of blood pressure control rate is that the percent of subjects with systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg
|
6 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D; American Heart Association; American Society of Hypertension; Preventive Cardiovascular Nurses Association. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. J Cardiovasc Nurs. 2008 Jul-Aug;23(4):299-323. doi: 10.1097/01.JCN.0000317429.98844.04.
- Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8.
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Internet Medical Model
-
Epitomee medicalAttivo, non reclutante
-
Wake Forest University Health SciencesCompletatoEmianopsia, omonima | Emianopsia, omonimaStati Uniti
-
Yale UniversityTerminatoQualità della vita | Schizofrenia | Aderenza ai farmaci | Segni e sintomi | Adattamento, psicologicoStati Uniti
-
Pyoeng Gyun ChoeTerminatoReti neurali profonde sull'accuratezza della diagnosi delle malattie della pelle nei non dermatologiMalattie della pelleCorea, Repubblica di
-
University of California, San DiegoReclutamentoAnoressia nervosaStati Uniti
-
Sun Yat-sen UniversityCompletato
-
Hasan Kalyoncu UniversityCompletatoMalattie polmonari, ostruttive | Malattia polmonare, cronica ostruttiva | Autogestione | Assistenza infermieristicaTacchino
-
Hacettepe UniversityCompletatoDiabete di tipo 2Tacchino
-
Charles G. ProberStanford University; Heidelberg University; University of Stellenbosch; University...CompletatoEsclusivo allattamento al seno | Pratiche di alimentazione infantileSud Africa